Africa's Underrepresentation in Medical Trials: A Global Health Bias

The article from Down To Earth highlights a critical and persistent bias in global medical research: despite bearing a significant portion of the world's disease burden, the African continent remains severely underrepresented in clinical trials. This underrepresentation has profound implications for global health equity, the development of effective treatments, and the applicability of medical science worldwide. The claims made in the article are strongly corroborated by numerous recent studies and reports from highly credible sources, including a landmark systematic review published in the *Journal of the American College of Cardiology (JACC)*. Africa is home to approximately 19% of the world's population, yet it accounts for roughly 25% of the global disease burden. The World Health Organization (WHO) estimates that nearly 630 million years of healthy life are lost annually in Africa due to disease, incurring an economic cost exceeding 2.4 trillion international dollars. This stark disparity between disease burden and research representation is a central theme across corroborating reports. A systematic review, analyzing 2,472 randomized controlled trials (RCTs) published between 2019 and 2024 in five top general medical journals, revealed that only 3.9% of these trials were conducted exclusively in Africa. The situation is even more dire in cardiovascular-specific journals, where a mere 0.6% of trials were Africa-only, and only 2.7% included any African participation. Other data indicates that Africa attracts less than 2% of registered clinical trials globally, hosted only 1.1% of all clinical trials worldwide in 2023 according to the WHO, and accounts for only 4% of global clinical trials despite its 25% disease burden. The consequences of this bias are far-reaching. The exclusion of African populations from biomedical and clinical research leads to biased evidence, incomplete biological understanding, reduced generalizability of findings, and suboptimal therapeutic interventions. When clinical trials are not inclusive, the results may not be fully applicable to diverse populations, potentially leading to varied treatment responses and side effects that are not understood for African individuals. This fundamentally limits the innovation potential in medical science and creates critical gaps in global health security. One significant issue highlighted is the skewed focus of research conducted within Africa. Studies show that nearly 76% of trials exclusively performed in Africa concentrate on infectious diseases. While infectious diseases remain a major concern, Africa is simultaneously undergoing a significant epidemiological transition. Non-communicable diseases (NCDs) such as heart disease, stroke, and diabetes are rapidly increasing and now account for about 38% of all deaths in many African nations. In fact, NCDs have surpassed infectious diseases as the largest contributors to productivity loss, representing 37% of the disease burden in 2019. Yet, research into these burgeoning NCDs on the continent remains severely underrepresented. For example, the aforementioned JACC study found only three Africa-only trials addressing cardiovascular disease, in stark contrast to the rapidly rising burden of cardiovascular disease on the continent. This imbalance means that the medical interventions developed globally may not be adequately tested or optimized for the unique genetic, environmental, and social contexts prevalent in African populations. Several factors contribute to this persistent underrepresentation. A primary barrier is the historical lack of robust infrastructure and resources dedicated to research in many African countries. This includes limited funding, inadequate facilities, and a shortage of trained researchers. Funding mechanisms often favor infectious diseases, neglecting the growing burden of NCDs. Furthermore, slow, duplicative approval processes and limited regulatory capacity can deter sponsors from conducting trials on the continent. Cultural beliefs, misconceptions, and past unethical research practices have also contributed to distrust and reluctance among African communities to participate in clinical research. Even when African sites are included in multi-continental trials, the inequity extends to leadership roles. African investigators rarely hold leadership positions in global studies, often being relegated to roles as "recruitment hubs" rather than scientific partners. This limits the opportunity for local expertise to shape research agendas and ensure cultural appropriateness and relevance. Moreover, the distribution of trials within Africa is also uneven; for instance, South Africa accounts for a disproportionately large share of the continent's trials (over 62%), while regions like Central Africa are almost entirely absent from global research records. The current situation not only impacts the health outcomes for Africans but also hinders global medical progress. Clinical trials are vital for advancing medical knowledge, developing new treatments, and ensuring the safety and efficacy of healthcare interventions for all populations. By excluding a significant portion of the world's genetic diversity, medical research risks producing incomplete evidence and missing crucial discoveries that could benefit global health. To address this systemic bias, experts call for a multi-faceted approach. This includes increased investment in African research infrastructure, capacity building for local researchers and healthcare providers, and funding for locally led studies. There is also a need for harmonized, simplified, and accelerated regulatory approval processes across African countries to attract more sponsors. Empowering local researchers is seen as critical for the success of clinical trials in Africa, fostering a more inclusive and comprehensive approach to medical research. Ultimately, correcting this bias is not merely an issue of representation but a fundamental matter of scientific validity, innovation, and global health equity. The article from Down To Earth, published on May 4, 2026, alongside other recent reports, underscores the pressing need for a fundamental shift in how global medical research prioritizes and includes the African continent.

Frequently Asked Questions

Read Full Story on Quick Digest